Relevance of the use of a combined hexavalent vaccine against pertussis, diphtheria, tetanus, hemophilus influenzae, poliomyelitis and hepatitis B


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The problems of timely and safe vaccination of children in the current epidemiological situation have acquired particular importance. Combined vaccines containing several antigens can increase the vaccination coverage of children in the first years of life, reduce the cost of vaccination, and minimize the number of errors in the introduction of vaccines. The data of recent studies on the immunological efficacy and safety of the combined hexavalent vaccine Infanrix Hexa are presented. The possibilities of interchangeability and mixed vaccination with the use of other vaccines against 6 infections, as well as in combination with vaccines against other infections are considered. The features of the use of the vaccine in special clinical settings in accordance with the current foreign and domestic regulatory documents are discussed.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Alla Tarasova

Privolzhsky Research Medical University

Email: taras.al@mail.ru
Dr. Sci. (Med.), Professor; Department of Faculty and Ouypatient Pediatrics 10/1, Minin and Pozharsky Sq., Nizhny Novgorod 603005, Russian Federation

M. Kostinov

I.I. Mechnikov Research Institute of Vaccines and Serums; Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia; Moscow, Russia

Әдебиет тізімі

  1. Maman K., Zöllner Y., Greco D., et al. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother 2015;11(9):2132-41. PMID: 26075806. doi: 10.1080/21645515.2015.1044180.
  2. Костинов М.П., Чучалин А.Г, Намазова- Баранова Л.С. и др. Приоритетная вакцинация респираторных инфекций в период пандемии SARS-COV-2 и после ее завершения. Пособие для врачей. Российское респираторное общество, Союз педиатров России, Евро-Азиатское общество по инфекционным болезням, Ассоциация детских инфекционистов, Независимый экспертный совет по вопросам иммунопрофилактики, ФГБНУ «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова». М., 2020. 32 с.
  3. Тактика формирования приверженности вакцинопрофилактике. Практическое руководство. Под ред. Н.И. Брико. M.: ГЭОТАР-Медиа, 2020. 168 с.
  4. Obando-Pacheco P., Rivero-Calle I., Gomez-Rial J., et al. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485-494. doi: 10.1016/j.vaccine.2017.06.063.
  5. World Health Organization. WHO recommendations for routine immunization -summary tables. [!nternet] 2016 [cited 2016 Aug 21]. URL: http://www.who.int/immunization/policy/immunization_tables/en
  6. Dolhain J., Janssens W., Mesaros N., et al. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer, Expert Review of Vaccines, 2018;17:6, 513-524. doi: 10.1080/14760584.2018.1419070.
  7. European Medicines Agency !nfarix hexa. Summary of Product Characteristics. 2000. [accessed 2018 April 30]. URL: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000296/WC500032505.pdf
  8. White paper to understand the market structure of pediatric pertussis combination vaccines. Disponibile online al. link: http://www.reportlinker.com/insight/white-paper-understand-market-structure-pediatric-pertussis-combination-vaccines.html.
  9. О локализации производства вакцин Инфанрикс Гекса и Синфлорикс в Российской Федерации. Педиатрическая фармакология. 2013;10(5):134.
  10. Защита от шести инфекций одной инъекцией. Педиатрическая фармакология. 2012;9(6):127-30.
  11. Таточенко В.К. Комбинированные вакцины в практике педиатра: когда коклюшная прививка в радость! Педиатрическая фармакология. 2012;9(4):26-31. Doi: https://doi.org/10.15690/pf.v9i4.386.
  12. Puente J., Verheust C., Hanssens L., et al. Safety profile of !nfanrix hexa - 17 years of GSK's passive post-marketing surveillance. Expert Rev Vaccines. 2020 Jul 30. doi: 10.1080/14760584.2020.1800458.
  13. Xu J., Stek J.E., Ziani E., et al. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine. Pediatr Infect Dis J. 2019;38(4):439-43. doi: 10.1097/INF0000000000002257.
  14. Gaudelus J., Vié le Sage F., Dufour V., et al. Public Health !mpact of Infanrix Hexa (DTPa-HBV-IPV/Hib) Reimbursement: A Study Programme in France. Part 1: Evolution of Hepatitis B Vaccine Coverage Rates in Infants Aged Less Than 27 Months, in the General Population - The PopCorn Study. Rev Epidemiol Sante Publique. 2016;64(1):23-32. doi: 10.1016/j.respe.2015.11.007.
  15. Vié le Sage F., Gaudelus J., Lert F., et al. Public Health !mpact of !nfanrix hexa™ (DTPa-HBV-!PV/Hib) Reimbursement: A Study Programme in France. Part 2: Evolution of the Acceptability of !nfants' Vaccination Against Hepatitis B in General and Pediatric Practices - The PRALINE Study. Rev Epidemiol Sante Publique. 2016;64(3):185-94. doi: 10.1016/j.respe.2015.12.019.
  16. World Health Organization. Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec. 2015;90(35):433-458.
  17. National Center for !mmunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on !mmunization Practices (AC!P). MMWR Recomm Rep. 2011;60(2):1-64.
  18. Langley J.M., Halperin S.A., Rubin E., et al. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. Pediatr Infect Dis J. 2012;31(2):189-92. doi: 10.1097/INF.0b013e318242462a.
  19. Puliyel J., Sathyamala C. !nfanrix hexa and sudden death: a review of the periodic safety update reports submitted to the European Medicines Agency. !ndian J Med Ethics. 2018;3(1):43-7. doi: 10.20529/IJME.2017.079.
  20. Шахтахтинская Ф.Ч., Гречуха Т.А., Ткаченко Н.Е. Опыт применения комбинированной гексавакцины у детей с отклонениями в состоянии здоровья. Практика педиатра. 2014;6:7-10
  21. Klein N.P., Abu-Elyazeed R., Cheuvart B., et al. !mmunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Hum Vaccin Immunother. 2019;15(4):809-21. doi: 10.1080/21645515.2018.1549449.
  22. Wang S., Tafalla M., Hanssens L., et al. A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16(11):1095-105. doi: 10.1080/14760584.2017.1383157.
  23. Monge S., Hahne S.J., de Melker H.E., et al. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study Lancet Infect Dis. 2018. doi: 10.1016/s1473-3099(18)30166-x.
  24. Van Der Meeren O., Behre U., Crasta P. Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine. Vaccine. 2016;34(24):2745-749. doi: 10.1016/j.vaccine.2016.04.013.
  25. Poovorawan Y., Chongsrisawat V.,Theamboonlers A., et al. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin !mmunother. 2013;9(8):1679-684. doi: 10.4161/hv.24844.
  26. Avdicova M., Crasta P.D., Hardt K., et al. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age. Vaccine. 2015;33(23):2727-733. doi: 10.1016/j.vaccine.2014.06.070.
  27. Schwarz T.F., Behre U., Adelt T., et al. Longterm antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Hum Vaccin !mmunother. 2019;15(1):235-241. Published online 2018 Sep
  28. doi: 10.1080/21645515.2018.1509658.28. Vesikari T., Silfverdal S., Jordanov E., et al. A randomized controlled study of DTaP-IPV-HB-PRP-T., a fully liquid hexavalent vaccine administered in a 3, 5 and 11 to 12 month schedule. Pediatr !nfect Dis J. 2017;36:87-93. doi: 10.1097/INF.0000000000001358.
  29. Silfverdal S., Icardi G., Vesikari T., et al. A phase III randomized double blind clinical trial of an investigational hexavalent vaccine given at 2, 4 and 11-12 months. Vaccine. 2016;34:3810-3816. doi: 10.1016/j.vaccine.2016.05.054.
  30. Whelan J., Hahné S., Berbers G., et al. !mmunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine. Findings from the National Immunisation Programme in The Netherlands. Hum Vaccin Immunother. 2012;8(6):743-48. doi: 10.4161/hv.19642.
  31. Иммунопрофилактика инфекционных болезней у недоношенных детей. Под ред. А.А. Баранова, Л.С. Намазовой-Барановой, И.А. Беляевой и др. M., Издательство «Педиатръ». 2020. 52 с.
  32. Infanrix Hexa®, RCP URL: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownload Servlet?pdfFileName=footer_000231_034960_RCPpdf&retry=0&sys=m0b1l3. Last accessed 23rd September, 2019.
  33. Chiappini E., Petrolini C., Sandini E., et al. Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology. Expert Rev Vaccines. 2019;18:523-545. doi: 10.1080/14760584.2019.1604230.
  34. Carbone T., McEntire B., Kissin D., et al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. Pediatrics. 2008;121:e1085-e1090. doi: 10.1542/peds.2007-2059.
  35. Deutsche Akademie für Kinder-und Jugendmedizin e.V Überwachung der Atmung bei ehemaligen Frühgeborenen (<28 Schwangerschaftswoche n) im Rahmen der Grundimmunisierung 2013. URL: https://dgpi.de/go/wp-content/uploads/2014/04/FG-Impfung_Ueberwachung_ DAKJ_Jul2013.pdf.
  36. Chiappini E., Petrolini C., Caffarelli C., et al. Hexavalent vaccines in preterm infants: an update by !talian Society of Pediatric Allergy and !mmunology jointly with the !talian Society of Neonatology. !tal J Pediatr. 2019;45:145. Published online 2019 Nov 19. doi: 10.1186/s13052-019-0742-7.
  37. Omeñaca F., Garcia-Sicilia J., Boceta R., et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr !nfect Dis J. 2007;26:824-29. doi: 10.1097/INF.0b013e318124a9c8.
  38. Omenaca F., Vazquez L., Garcia-Corbeira P., et al. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine. 2018;36(7):986-96. doi: 10.1016/j.vaccine.2018.01.005.
  39. Деордиева Е.А., Балашов Д.Н., Скворцова Ю.В. и др. Современный взгляд на проблему вакцинопрофилактики пациентов после трансплантации гемопоэтических стволовых клеток и рекомендации к ее проведению в Российской Федерации. Педиатрия. 2019;98(3):135-44. doi: 10.24110/0031-403X-2019-98-3-135-44.
  40. Papadopoulos E.B., Young J.W., Kernan N.A. et al. Use of the Tetanus Toxoid, Reduced Dose Diphtheria and Pertussis Vaccine (Tdap) in Allogeneic Transplant (alloHCT) Recipients. Blood. 2008;112(11):2214. doi.org/10.1182/blood. V112.11.2214.2214

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>